Snapshot from Jul 07, 2026 at 07:00 UTC. For live data and tracking: View Live
Company

Ultragenyx

Tracked across 3 events · 44 articles · First seen Feb 05, 2026 · Last active May 27, 2026

Sentiment
0
Attention
4
Events
3
Relationships
0
Live sentiment trends, attention charts, and prominence tracking available on the Ergen Dashboard
4 70
Regulatory
Impact: Ultragenyx announced that the United States — Food and Drug Administration accepted its resubmitted Biologics License Application for UX111, bringing it closer to potential approval for Sanfilippo syndrome Type A.
Apr 02, 2026 · 6 articles
4 -70
Business
Impact: Ultragenyx is the defendant in a class action lawsuit alleging that it made false and misleading statements regarding its Phase III Orbit and Cosmic Studies for setrusumab, leading to a significant drop in its stock price.
Feb 05, 2026 · 31 articles
4 0
Business
Impact: Ultragenyx is currently facing a pending lawsuit from the estate of Henrietta Lacks regarding the use of HeLa cells.
Feb 26, 2026 · 7 articles
ERGEN INTELLIGENCE
Track Ultragenyx live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.